Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W20 prize-linked savings/sweepstakes fintech at 700K+ members; severely impacted by Synapse bankruptcy May 2024 leaving 85K customers unable to access $112M in deposits; $17.9M total ($13.2M Base10 Series A 2021).
Yotta is a New York-based fintech company — backed by Y Combinator (W20) with $17.9-21.2 million in total funding including a $13.2 million Series A in January 2021 led by Base10 Partners with Y Combinator, Core Innovation Capital, and Slow Ventures — offering sweepstakes games with a member base of 700,000+ people, after previously operating prize-linked savings accounts before being severely impacted by the Synapse Financial Technologies bankruptcy in May 2024. When Synapse (Yotta's banking-as-a-service middleware partner) failed, approximately 85,000 Yotta customers with $112 million in deposits lost account access — and as of November 2024, 13,725 depositors were offered only $11.8 million of $64.9 million in claimed deposits, illustrating the systemic risk that BaaS middleware dependency creates for fintech customer funds.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.